WeVote
Log In

Bill

Bill

S 6422

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

2025 Regular Session Introduced by Jeremy Cooney and 1 co-sponsor

Bill S 6422 mandates clearer prescription labels for hormone-related medications, enhancing patient understanding and safety, improving adherence, and supporting healthcare providers.

REFERRED TO HIGHER EDUCATION
0
WeVote Research Nonpartisan
Bill Summary · S 6422

Summary of Bill S 6422

Bill Information

  • Bill Number: S 6422
  • Title: Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy
  • Status: Referred to Higher Education
  • Introduced: March 13, 2025
  • Classification: Bill
  • Related Bills: A 6927 (companion)

Purpose and Intent

Bill S 6422 aims to enhance the clarity and safety of prescription labels for specific classes of medications, including:
- Gonadotropin-releasing hormone agonists
- Pubertal suppressants
- Anabolic steroids
- Alpha reductase inhibitors
- Progestins
- Drugs used for hormone replacement therapy

The primary intent of the bill is to ensure that patients and healthcare providers have access to clear, comprehensive information regarding the use, benefits, and potential risks associated with these medications. This is particularly important for drugs that may have significant implications for hormonal health and development.

Key Provisions

The bill proposes the following key provisions:
- Labeling Requirements: Establishes specific requirements for the content and format of prescription labels for the aforementioned drug classes. This may include:
- Clear dosage instructions
- Potential side effects
- Warnings about interactions with other medications
- Information on the intended use and benefits of the medication
- Patient Education: Mandates that healthcare providers offer educational materials that accompany prescriptions, ensuring patients understand their treatment options and the importance of adherence to prescribed therapies.

Impact

Who Would Be Affected

  • Patients: Individuals prescribed these medications will benefit from clearer information, potentially leading to better adherence to treatment regimens and improved health outcomes.
  • Healthcare Providers: Physicians, pharmacists, and other healthcare professionals will have standardized labeling to reference, which can enhance patient consultations and education.
  • Pharmaceutical Companies: Manufacturers of these medications will need to comply with the new labeling requirements, which may involve revising existing packaging and informational materials.

Procedural Aspects

  • Current Status: As of March 13, 2025, the bill has been referred to the Higher Education committee for further consideration. The timeline for subsequent actions, including potential hearings or votes, has not yet been established.

Conclusion

Bill S 6422 represents a significant step towards improving the safety and effectiveness of hormone-related therapies through enhanced prescription labeling. By ensuring that patients receive clear and comprehensive information, the bill aims to foster better health outcomes and informed decision-making in the use of these critical medications.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.